ESC Premium Access

Real-world effectiveness of stroke prevention in patients with non-valvular atrial fibrillation treated with rivaroxaban vs. phenprocoumon in germany - insights from the reload study

Congress Presentation

About the speaker

Professor Hendrik Bonnemeier

Schleswig-Holstein University Clinic, Lubeck Campus, Luebeck (Germany)
6 presentations
0 follower

53 more presentations in this session

Differences between randomized controlled clinical trials and real-world atrial fibrillation patients treated with oral anticoagulants - do we treat the same patients? Results from the CRAFT study

Speaker: Doctor A. Tyminska (Warsaw, PL)


Which factors influence the choice of a non-vitamin K oral anticoagulant over warfarin for stroke prevention among atrial fibrillation patients? Insights from the prospective SPRINT-AF registry.

Speaker: Doctor M. Gupta (Toronto, CA)


Increased thromboprophylactic treatment of patients with atrial fibrillation after the introduction of NOACs - an analysis of sex and gender differences

Speaker: Ms D. Loikas (Stockholm, SE)


Comparison of stroke- and bleed-related healthcare resource utilization (HCRU) among patients with non-valvular atrial fibrillation (NVAF), newly treated with oral anti-coagulants (OACs)

Speaker: Doctor J. Franchino-Elder (Ridgefield, US)


Real-world single tertiary-care multidisciplinary experience with dabigatran, apixaban, rivaroxaban and warfarin in patients with renal failure and concomitant NVAF.

Speaker: Doctor F. Melillo (Milan, IT)


Access the full session

Poster session 4 - Stroke prevention

Speakers: Professor H. Bonnemeier, Doctor A. Tyminska, Doctor M. Gupta, Ms D. Loikas, Doctor J. Franchino-Elder...

About the event


ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb